ArticleFrontiers in immunology2026
Case Report: Acute interstitial pneumonia as the initial presentation of Anti-EJ antisynthetase syndrome: a case of severe respiratory failure with rapid response to cyclophosphamide.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antisynthetase syndrome (ASyS) associated with anti-EJ antibodies (directed against glycyl-tRNA synthetase) is increasingly recognized as an ILD-dominant phenotype with a propensity for rapidly progressive ILD (RP-ILD). Acute interstitial pneumonia (AIP)-like presentations may mimic severe infection, posing significant diagnostic challenges. Case presentation: A 55-year-old man with hypertension and a 20-pack-year smoking history presented with a fever (39°C) and rapidly progressive dyspnea. Laboratory findings revealed markedly elevated inflammatory markers. CT pulmonary angiogram demonstrated diffuse bilateral ground-glass opacities, consolidations, and interlobular septal thickening consistent with AIP-pattern. Despite broad-spectrum antibiotics, the patient developed refractory respiratory failure requiring mechanical ventilation, hemodynamic instability requiring vasopressors, and acute kidney injury. Bronchoscopy with transbronchial biopsy confirmed acute interstitial inflammation. After more than one week in the intensive care unit (ICU) without improvement, rheumatologic evaluation revealed positive for anti-EJ and anti-Th/To antibodies, supporting ASyS. High-dose of immunosuppressive drug were initiated, resulting in marked improvement in oxygenation, hemodynamics, and muscle strength within 48 hours. Follow-up CT at three weeks demonstrated significant regression of ground-glass opacities with residual findings consistent with nonspecific interstitial pneumonia/usual interstitial pneumonia (NSIP/UIP) overlap. Conclusion: ASyS should be considered in patients with severe pneumonia-like illness who fail to respond to appropriate antibiotic therapy. Anti-EJ antibodies are associated with AIP-like patterns and fulminant respiratory failure. Early serologic testing and prompt immunosuppression can be life-saving. The recently published 2024 Classification Criteria for Anti-Synthetase Syndrome (CLASS) provide a contemporary framework for the classification of ASyS, particularly in ILD-dominant presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.